Development of a 3D lung model to investigate fibrotic lung disease
Research type
Research Study
Full title
Development of a 3 dimensional organotypic lung model to investigate the response to injury and the pathological basis of dysrepair in both healthy and fibrotic lung.
IRAS ID
133710
Contact name
Ling-Pei Ho
Contact email
Sponsor organisation
Oxford Radcliffe Hospitals NHS Trust
Research summary
Pulmonary fibrosis (IPF) is a chronic and fatal lung disease that can be linked to certain autoimmune diseases and inflammatory conditions, but often has an unknown cause (termed Idiopathic Pulmonary Fibrosis (IPF)). The median survival of IPF is 2–5 years (Selman M et al Ann Intern Med 2001), and all patients show progressive deterioration, although the rate of decline is variable. The pathogenic processes involved are difficult to investigate, and therefore therapeutic targets hard to identify. The cause of the heterogeneous clinical course is virtually unknown and under-researched, and there is no way of predicting how patients will fare once diagnosis is made.
This project aims to generate a 3 dimensional in-vitro organotypic model of both fibrotic and normal lung, to provide a cellular model to examine potential fibrogenic cellular and protein targets and pathways that may contribute to the pathogenic processes involved in the disease process.REC name
South Central - Oxford B Research Ethics Committee
REC reference
13/SC/0420
Date of REC Opinion
14 Feb 2014
REC opinion
Further Information Favourable Opinion